- Home
- TNYA vs MGNX Comparison
TNYA vs MGNX Comparison
Compare TNYA & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNYA
- MGNX
- Stock Information
- Founded
- TNYA 2016
- MGNX 2000
- Country
- TNYA United States
- MGNX United States
- Employees
- TNYA N/A
- MGNX N/A
- Industry
- TNYA Medicinal Chemicals and Botanical Products
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- TNYA Health Care
- MGNX Health Care
- Exchange
- TNYA Nasdaq
- MGNX Nasdaq
- Market Cap
- TNYA 138.1M
- MGNX 257.3M
- IPO Year
- TNYA 2021
- MGNX 2013
- Fundamental
- Price
- TNYA $1.67
- MGNX $3.17
- Analyst Decision
- TNYA Strong Buy
- MGNX Hold
- Analyst Count
- TNYA 4
- MGNX 10
- Target Price
- TNYA $17.33
- MGNX $7.17
- AVG Volume (30 Days)
- TNYA 7.5M
- MGNX 485.4K
- Earning Date
- TNYA 11-06-2024
- MGNX 11-05-2024
- Dividend Yield
- TNYA N/A
- MGNX N/A
- EPS Growth
- TNYA N/A
- MGNX N/A
- EPS
- TNYA N/A
- MGNX N/A
- Revenue
- TNYA N/A
- MGNX $141,329,000.00
- Revenue This Year
- TNYA N/A
- MGNX $174.73
- Revenue Next Year
- TNYA N/A
- MGNX N/A
- P/E Ratio
- TNYA N/A
- MGNX N/A
- Revenue Growth
- TNYA N/A
- MGNX 16.68
- 52 Week Low
- TNYA $0.99
- MGNX $2.95
- 52 Week High
- TNYA $7.01
- MGNX $21.88
- Technical
- Relative Strength Index (RSI)
- TNYA 37.59
- MGNX 41.22
- Support Level
- TNYA $0.99
- MGNX $3.10
- Resistance Level
- TNYA $3.69
- MGNX $3.45
- Average True Range (ATR)
- TNYA 0.40
- MGNX 0.20
- MACD
- TNYA -0.27
- MGNX -0.01
- Stochastic Oscillator
- TNYA 22.59
- MGNX 17.24
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).